RXRA
Retinoic acid receptor RXR-alpha
Also known as: NR2B1, RXR-alpha, RXRA_HUMAN, RXRalpha
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P19793
- Gene
- RXRA
- Ensembl
- ENSG00000186350
- Chromosome
- 9
- Canonical length
- 462 aa
- Protein class
- Cancer-related genes, FDA approved drug targets, Metabolic proteins, Nuclear receptors, Predicted intracellular proteins, Transcription factors
- Subcellular location
- Nucleoplasm,Golgi apparatus
- Quaternary structure
- Homodimer
OverviewNCBI Gene
Retinoid X receptors (RXRs) and retinoic acid receptors (RARs) are nuclear receptors that mediate the biological effects of retinoids by their involvement in retinoic acid-mediated gene activation. These receptors function as transcription factors by binding as homodimers or heterodimers to specific sequences in the promoters of target genes. The protein encoded by this gene is a member of the steroid and thyroid hormone receptor superfamily of transcriptional regulators. Alternative splicing of this gene results in multiple transcript variants. [provided by RefSeq, May 2014]
Canonical amino-acid sequenceUniProt
462 residues, UniProt reviewed canonical sequence.
>P19793|RXRA
1 MDTKHFLPLD FSTQVNSSLT SPTGRGSMAA PSLHPSLGPG IGSPGQLHSP ISTLSSPING
61 MGPPFSVISS PMGPHSMSVP TTPTLGFSTG SPQLSSPMNP VSSSEDIKPP LGLNGVLKVP
121 AHPSGNMASF TKHICAICGD RSSGKHYGVY SCEGCKGFFK RTVRKDLTYT CRDNKDCLID
181 KRQRNRCQYC RYQKCLAMGM KREAVQEERQ RGKDRNENEV ESTSSANEDM PVERILEAEL
241 AVEPKTETYV EANMGLNPSS PNDPVTNICQ AADKQLFTLV EWAKRIPHFS ELPLDDQVIL
301 LRAGWNELLI ASFSHRSIAV KDGILLATGL HVHRNSAHSA GVGAIFDRVL TELVSKMRDM
361 QMDKTELGCL RAIVLFNPDS KGLSNPAEVE ALREKVYASL EAYCKHKYPE QPGRFAKLLL
421 RLPALRSIGL KCLEHLFFFK LIGDTPIDTF LMEMLEAPHQ MTLocalizationUniProt · AlphaFold · HPA
Whether an antibody against RXRA can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.43
- Highest tissue expression
- 121 nTPM
Expression across tissuesHPA
Tissue
- skeletal muscle: 121 nTPM
- liver: 112 nTPM
- skin: 83 nTPM
- tongue: 48 nTPM
- parathyroid gland: 42 nTPM
- esophagus: 40 nTPM
Single-cell type
- neutrophils: 314 nCPM
- hepatocytes: 249 nCPM
- kupffer cells: 189 nCPM
- esophageal apical cells: 163 nCPM
- thymic myoid cells: 156 nCPM
- monocytes: 150 nCPM
Immune cell
- neutrophil: 20 nTPM
- intermediate monocyte: 13 nTPM
- non-classical monocyte: 11 nTPM
- classical monocyte: 8.1 nTPM
- eosinophil: 6.7 nTPM
- myeloid DC: 3.2 nTPM
Brain region
- thalamus: 79 nTPM
- basal ganglia: 64 nTPM
- amygdala: 59 nTPM
- medulla oblongata: 57 nTPM
- midbrain: 54 nTPM
- pons: 54 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about RXRA.
Disease | GeneticClinVar
1 pathogenic / likely-pathogenic of 40 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.16
- gnomAD pLI
- 1
- gnomAD missense Z
- 2.97
- DepMap mean gene effect
- -0.07
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- cell differentiation
- cell maturation
- cellular response to low-density lipoprotein particle stimulus
- hormone-mediated signaling pathway
- monocyte differentiation
- mRNA transcription by RNA polymerase II
- negative regulation of transcription by RNA polymerase II
- nervous system development
- peroxisome proliferator activated receptor signaling pathway
- positive regulation of bone mineralization
- positive regulation of cholesterol efflux
- positive regulation of DNA-templated transcription
- positive regulation of lipid metabolic process
- positive regulation of lipoprotein transport
- positive regulation of thyroid hormone receptor signaling pathway
- positive regulation of transcription by RNA polymerase II
- positive regulation of vitamin D receptor signaling pathway
- response to retinoic acid
- retinoic acid receptor signaling pathway
Molecular functions
- DNA binding domain binding
- DNA-binding transcription factor activity
- DNA-binding transcription factor activity, RNA polymerase II-specific
- double-stranded DNA binding
- enzyme binding
- identical protein binding
- LBD domain binding
- nuclear receptor activity
- nuclear steroid receptor activity
- nuclear vitamin D receptor binding
- peptide binding
- retinoic acid binding
- retinoic acid-responsive element binding
- RNA polymerase II cis-regulatory region sequence-specific DNA binding
- RNA polymerase II transcription regulatory region sequence-specific DNA binding
- sequence-specific DNA binding
- sequence-specific double-stranded DNA binding
- transcription cis-regulatory region binding
- transcription coregulator binding
- zinc ion binding
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Retinoid X receptor/HNF4
- Nuclear hormone receptor, ligand-binding domain
- Zinc finger, nuclear hormone receptor-type
- Nuclear hormone receptor
- Zinc finger, NHR/GATA-type
- Nuclear/hormone receptor activator site AF-1
- Nuclear hormone receptor-like domain superfamily
- Nuclear hormone receptor family NR2 subfamily
- Ligand-binding domain of nuclear hormone receptor
- Double treble clef zinc finger, C4 type
- Nuclear/hormone receptor activator site AF-1
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of RXRA in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads RXRA as an antibody target. Whether an autoantibody or antibody against RXRA could matter depends on whether native RXRA is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
RXRA is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label RXRA as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...